What do systematic reviews say?

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Thrombopoietin mimetics vs placebo or usual care

The review found no eligible studies for this question.

• Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

• A therapeutic‐only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

mTOR inhibitors vs chemotherapy/hormone therapy

The review found no eligible studies for this question.

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

The review found no eligible studies for this question.

• Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

The review found no eligible studies for this question.

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose strategies

The review found no eligible studies for this question.

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule

The review found no eligible studies for this question.

• Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported